Stockscreener 앱 받기
8.50
1.19%
0.10
전일 마감가:
$8.40
열려 있는:
$8.46
하루 거래량:
482.90K
Relative Volume:
0.48
시가총액:
$478.53M
수익:
$27.46M
순이익/손실:
$-46.05M
주가수익비율:
-6.5891
EPS:
-1.29
순현금흐름:
$-33.83M
1주 성능:
-1.16%
1개월 성능:
-4.71%
6개월 성능:
-9.86%
1년 성능:
+6.38%
1일 변동 폭
$8.4501
$8.70
1주일 범위
$8.25
$8.73
52주 변동 폭
$6.19
$13.16
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
명칭
Zevra Therapeutics Inc
전화
(321) 939-3416
주소
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Compare ZVRA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
8.50 | 472.90M | 27.46M | -46.05M | -33.83M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-02 | 개시 | H.C. Wainwright | Buy |
| 2025-01-08 | 재개 | Cantor Fitzgerald | Overweight |
| 2024-10-07 | 개시 | Guggenheim | Buy |
| 2024-09-24 | 개시 | JMP Securities | Mkt Outperform |
| 2024-09-24 | 재확인 | Maxim Group | Buy |
| 2024-04-02 | 재확인 | Maxim Group | Buy |
| 2024-03-12 | 개시 | William Blair | Outperform |
| 2023-03-17 | 개시 | Maxim Group | Buy |
모두보기
Zevra Therapeutics Inc 주식(ZVRA)의 최신 뉴스
Will Zevra Therapeutics Inc. benefit from geopolitical trendsWeekly Trade Recap & Capital Protection Trading Alerts - mfd.ru
Neil F. McFarlane, Zevra Therapeutics president, sells $125k in shares - Investing.com Canada
Stock Analysis: What is the implied volatility of Zevra Therapeutics IncEarnings Growth Report & Technical Confirmation Alerts - baoquankhu1.vn
Zevra Therapeutics opens Nasdaq with bell ceremony - Traders Union
Zevra Therapeutics Rings the Opening Bell - Nasdaq
Responsive Playbooks and the ZVRA Inflection - Stock Traders Daily
Zevra Therapeutics, Inc. (ZVRA) Investor Outlook: Unpacking a 169.66% Potential Upside with Robust Revenue Growth - DirectorsTalk Interviews
Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA in Patients with Neimann-Pick Disease Type C at the 22nd Annual WorthLDSymposium - marketscreener.com
ZVRA: Zevra Therapeutics Unveils Promising Data on Miplyffa at W - GuruFocus
Zevra Therapeutics Presents Positive Data on MIPLYFFA® for Niemann-Pick Disease Type C at WORLDSymposium™ 2026 - Quiver Quantitative
4 years of real-world data track MIPLYFFA in rare Niemann-Pick disease - Stock Titan
Joshua Schafer Sells 10,500 Shares of Zevra Therapeutics (NASDAQ:ZVRA) Stock - MarketBeat
Schafer Joshua, CCO of Zevra, sells $29,800 in ZVRA stock By Investing.com - Investing.com Australia
Schafer Joshua, CCO of Zevra, sells $29,800 in ZVRA stock - Investing.com
Zevra Therapeutics (NASDAQ:ZVRA) Insider Sells $29,801.25 in Stock - MarketBeat
Zevra Therapeutics (NASDAQ:ZVRA) Insider Sells $40,026.39 in Stock - MarketBeat
Neil Mcfarlane Sells 91,000 Shares of Zevra Therapeutics (NASDAQ:ZVRA) Stock - MarketBeat
Insider Selling: Zevra Therapeutics (NASDAQ:ZVRA) SVP Sells 1,750 Shares of Stock - MarketBeat
Zevra Therapeutics CEO McFarlane sells $853k in shares By Investing.com - Investing.com South Africa
Zevra Therapeutics CEO McFarlane sells $853k in shares - Investing.com
Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026 - The Manila Times
Published on: 2026-02-02 12:45:20 - baoquankhu1.vn
Portfolio Shifts: Can Zevra Therapeutics Inc maintain sales growthJuly 2025 Spike Watch & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Layoff Watch: Does Zevra Therapeutics Inc have declining or rising EPS2025 Growth vs Value & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Short Interest Down 32.5% in January - MarketBeat
Is Zevra Therapeutics Inc. forming bullish engulfing patternsMarket Movement Recap & Expert Verified Stock Movement Alerts - mfd.ru
Zevra Therapeutics, Inc. (ZVRA) Stock Analysis: Exploring a Promising 154% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Understanding the Setup: (ZVRA) and Scalable Risk - Stock Traders Daily
Delaware Chancery Court Ruling Finds a Security Interest is a “Transfer” – Commave v. Zevra - The National Law Review
Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™ - GlobeNewswire
Investing in Zevra Therapeutics (NASDAQ:ZVRA) three years ago would have delivered you a 63% gain - Yahoo Finance
Zevra Therapeutics (NASDAQ:ZVRA) Trading 5.2% HigherHere's What Happened - MarketBeat
ZVRA Stock Price and Chart — NASDAQ:ZVRA - TradingView
Insider Buy: What is Zevra Therapeutics Incs market positionJuly 2025 Recap & AI Powered Market Entry Strategies - baoquankhu1.vn
Volume Recap: Will Zevra Therapeutics Inc benefit from geopolitical trendsEarnings Risk Report & Low Risk Growth Stock Ideas - baoquankhu1.vn
The Technical Signals Behind (ZVRA) That Institutions Follow - Stock Traders Daily
Published on: 2026-01-17 12:49:06 - baoquankhu1.vn
J.P. Morgan: Zevra Sees EU As Land Of Opportunity For Miplyffa - Citeline News & Insights
Zevra Therapeutics (ZVRA) Announces Positive New Data Supporting Foundational Role of MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C - MSN
Is Zevra Therapeutics (ZVRA) Using J.P. Morgan Spotlight To Reframe Its Rare-Disease Investment Story? - simplywall.st
Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates - MSN
Zevra Therapeutics Reports Strong Q3 Earnings and Strategic Growth - MSN
Zevra Therapeutics FY 2024 Earnings Preview - MSN
Can Zevra Therapeutics Inc. stock withstand economic slowdownJuly 2025 Sentiment & Verified Entry Point Signals - Улправда
How Zevra Therapeutics Inc. stock benefits from tech adoptionJuly 2025 Rallies & Expert Approved Trade Ideas - ulpravda.ru
Can Zevra Therapeutics Inc. stock double in next 5 yearsJuly 2025 Gainers & Reliable Volume Spike Alerts - Улправда
Can Zevra Therapeutics Inc. stock sustain revenue growthTrade Performance Summary & Stock Market Timing Techniques - ulpravda.ru
Is Zevra Therapeutics Inc. stock a top pick in earnings season2025 Risk Factors & Fast Gain Swing Alerts - Улправда
Will Zevra Therapeutics Inc. stock deliver strong dividend growthWeekly Gains Report & Verified Momentum Stock Ideas - ulpravda.ru
What Wall Street predicts for Zevra Therapeutics Inc. stock priceAnalyst Downgrade & Precise Entry and Exit Recommendations - Улправда
Zevra Therapeutics Inc (ZVRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Zevra Therapeutics Inc 주식 (ZVRA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Sangiovanni Timothy J. | SVP, Finance & Corp Controller |
Feb 03 '26 |
Sale |
9.18 |
3,000 |
27,548 |
29,590 |
| Schafer Joshua | CCO |
Feb 03 '26 |
Sale |
9.19 |
10,500 |
96,500 |
62,278 |
| Sangiovanni Timothy J. | SVP, Finance & Corp Controller |
Jan 30 '26 |
Sale |
8.82 |
1,750 |
15,442 |
20,924 |
| Thompson Rahsaan | Chief Legal & Compliance |
Jan 30 '26 |
Sale |
8.83 |
4,080 |
36,010 |
49,919 |
| Quartel Adrian W | Chief Medical Officer |
Jan 30 '26 |
Sale |
8.83 |
4,533 |
40,036 |
9,723 |
| Schafer Joshua | CCO |
Jan 30 '26 |
Sale |
8.83 |
3,375 |
29,800 |
37,444 |
| McFarlane Neil F. | President and CEO |
Feb 02 '26 |
Sale |
9.38 |
91,000 |
853,425 |
364,350 |
1.12%
0.87%
자본화:
|
볼륨(24시간):